Prenetics Global Limited (NASDAQ:PRE) Short Interest Down 17.6% in February

Prenetics Global Limited (NASDAQ:PRE) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 32,800 shares, a drop of 17.6% from the February 13th total of 39,800 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average trading volume of 13,600 shares, the short-interest ratio is currently 2.4 days.

Prenetics Global Trading Down 6.1 %

NASDAQ PRE traded down $0.28 during trading hours on Tuesday, hitting $4.25. 6,873 shares of the company’s stock traded hands, compared to its average volume of 39,378. Prenetics Global has a 52 week low of $2.85 and a 52 week high of $7.84. The firm has a market capitalization of $51.81 million, a P/E ratio of -1.06 and a beta of -0.31. The business’s fifty day moving average price is $5.29 and its two-hundred day moving average price is $4.97.

Institutional Investors Weigh In On Prenetics Global

A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC acquired a new stake in shares of Prenetics Global Limited (NASDAQ:PRE) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned about 0.10% of Prenetics Global as of its most recent SEC filing. Hedge funds and other institutional investors own 25.01% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $9.00 price objective on shares of Prenetics Global in a research note on Thursday, January 16th.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.